Endothelin pp 223-268 | Cite as

Pathophysiological Role of Endothelin and Potential Therapeutic Targets for Receptor Antagonists

  • David P. Brooks
  • Diane K. Jorkasky
  • Martin I. Freed
  • Eliot H. Ohlstein
Chapter
Part of the Contemporary Biomedicine book series (CB)

Abstract

In the decade following the discovery of endothelin (ET) by Yanagisawa and his colleagues (1), there has been a prodigious number of studies on endothelin, its receptors, and their potential role in physiological and pathophysiological processes. There is an ever-increasing literature describing the importance of endothelin and the potential use of ET-receptor antagonists in a number of diverse diseases (Table 1). A detailed description of the evidence implicating endothelin in all the diseases listed as well as citing all the relevant papers cannot be conducted within the confines of one chapter. We have, on occasion, therefore, used review articles in place of multiple citations and have concentrated our discussion on four disease areas for which there is the most evidence and provide brief descriptions of some of the other areas for which reports have appeared. As ET-receptor antagonists enter clinical development and different clinical trials are conducted, it is likely that some of these “other diseases” take more prominent positions with regard to intervention with endothelin antagonists.

Keywords

Acute Renal Failure Cerebral Vasospasm Late Asthmatic Response Ischemic Acute Renal Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond) 332: 411–415.CrossRefGoogle Scholar
  2. 2.
    Vierhapper, H., Wagner, O., Nowotny, P., and Waldhausl, W. (1990) Effect of endothelin-1 in man. Circulation 81: 1415–1418.Google Scholar
  3. 3.
    Sorensen, S. S., Madsen, J. K., and Pedersen, E. B. (1994) Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am. J. Physiol 266: F411 — F418.PubMedGoogle Scholar
  4. 4.
    Rabelink, T. J., Kaasiager, K. A. H., Boer, P., Stroes, E. G., Braam, B., and Koomans, H. A. (1994) Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 46: 376–381.PubMedCrossRefGoogle Scholar
  5. 5.
    Yokokawa, K., Tahara, H., Kohno, M., Murakawa, K., Yasunari, K., Nakagawa, K., Hamada, T., Otani, S., Yanagisawa, M., and Takeda, T. (1991) Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann. Intern. Med. 114:213–215.Google Scholar
  6. 6.
    Wilkes, F. C., Jr., Alberola, A., Mizelle, H. L., Opgenorth, T. J., and Granger, J. P. (1993) Chronic pathophysiological circulating endothelin levels produce hypertension in conscious dogs. J. Cardiovasc. Pharmacol. 22(Suppl. 8 ): S325 — S327.Google Scholar
  7. 7.
    Niranjan, V., Telemaque, S., Dewit, D Gerard, R. D., and Yanagisawa, M. (1996) Systemic hypertension induced by hepatic overexpression of human prepro-endothelin-1 in rats. J. Clin. Invest 98:2364–2372 Google Scholar
  8. 8.
    Jorkasky, D. K., Hay, D. W. P. and Freed, M. I. (1995) The role of endothelin in human disease: implications and potential therapeutic intervention, in Endothelin Receptors: From the Gene to the Human (Ruffolo, R. R., Jr., ed.), CRC, Boca Raton, FL, pp. 215–271.Google Scholar
  9. 9.
    Letizia, C., Cerci, S., De Ciocchis, A., D’Ambrosio, C., Scuro, L., and Scavo, D. (1995) Plasma endothelin-1 levels in normotensive and borderline hypertensive subjects during a standard cold pressor test. J. Hum. Hypertens. 9:903–907.Google Scholar
  10. 10.
    Ergul, S., Parish, D. C., Puett, D., and Ergul, A. (1996) Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28: 652–655.PubMedCrossRefGoogle Scholar
  11. 11.
    Ohlstein, E. H., Douglas, S. A., Brooks, D. P., Hay, D. W. P., Feuerstein, G. Z., and Ruffolo, R. R., Jr. (1995) Functions mediated by peripheral endothelin receptors, in Endothelin Receptors: From the Gene to the Human ( Ruffolo, R. R., Jr., ed.), CRC, Boca Raton, FL, pp. 109–185.Google Scholar
  12. 12.
    Larivière, R., Thibault, G., and Schiffrin, E. (1993) Increase endothelin1 content in blood vessels of deoxycorticosterone acetate-salt hypertension but not in spontaneously hypertensive rats. Hypertension 21: 294–300.PubMedCrossRefGoogle Scholar
  13. 13.
    Wong, M. and Jeng, A. Y. (1989) Parallel increases in cardiac endothelin and blood pressure of spontaneously hypertensive rats. Pharmacologist 31: 374 P.Google Scholar
  14. 14.
    Fujita, K., Matsumura, Y., Miyazaki, Y., Hashimoto, N., Takaoka, M., and Morimoto, S. (1996) ETA receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats. Life Sci. 58:PL1—PL7.Google Scholar
  15. 15.
    Takada, K., Matsumura, Y., Dohmen, S., Mitsutomi, N., Takaoka, M., and Morimoto, S. (1996) Endothelin-1 secretion from cultured vascular endothelial cells of DOCA-salt hypertensive rats. Life Sci. 59:PL111 PL116.Google Scholar
  16. 16.
    Schiffrin, E. L., Lariviere, R., and Touyz, R. M. (1995) ETA and ETB receptors on vascular smooth muscle cells from mesenteric vessels of spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 22(Suppl. 1 ), 5193, 5194.Google Scholar
  17. 17.
    Hocher, B., Rohmeiss, P., Zart, R., Diekmann, F., Vogt, V., Metz, D., Fakhury, M., Gretz, N., Bauer, C., Koppenhagen, K., Neumayer, H. H., and Distler, A. (1996) Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc. Res 31: 499–510.PubMedGoogle Scholar
  18. 18.
    Hiraoka, J., Arai, H., Yoshimasa, T., Takaya, K., Miyamoto, Y., Yamashita, J., Suga, S., Ogawa, Y., Shirakami, G., and Itoh, H. (1995) Augmented expression of the endothelin-A receptor gene in cultured mesangial cells from stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 22(Suppl. 1):S191—S192.Google Scholar
  19. 19.
    Gellai, M., DeWolf, R., Pullen, M., and Nambi, P. (1994) Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int. 46:1287–1294.Google Scholar
  20. 20.
    Gu, X.-H., Casley, D. J., Cincotta, M., and Nayler, W. G. (1990) 125IEndothelin-1 binding to brain and cardiac membranes from normotensive and spontaneously hypertensive rats. Eur. J. Pharmacol 177: 205–209.Google Scholar
  21. 21.
    Evangelista, S., Maggi, C.A., and Castellucci, A. (1992) Effect of endothelin (ET)-1, ET-3 and ET-(16–21) on the isolated and perfused rat kidney from normotensive and spontaneously hypertensive rats. Jpn. J. Pharmacol 59: 239–241.PubMedCrossRefGoogle Scholar
  22. 22.
    Goligorsky, M. S., Iijima, K., Morgan, M., Yanagisawa, M., Masaki, T., Lin, L., Nasjletti, A., Kaskel, F., Frazer, M., and Badr, K. F. (1991) Role of endothelin in the development of Dahl hypertension. J. Cardiovasc. Pharmacol. 17(Suppl. 7 ): S484 — S491.Google Scholar
  23. 23.
    Ohno, A., Naruse, M., Kato, S., Hosaka, M., Karuse, K., and Demura, H. (1992) Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats. J. Hypertens 10: 781–785.PubMedCrossRefGoogle Scholar
  24. 24.
    Kato, T., Kassab, S., Wilkins, F. C., Jr., Kirchner, K. A., Keiser, J., and Granger, J. P. (1995) Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension 25(part 2): 883–887.Google Scholar
  25. 25.
    McMahon, E. G., Palomo, M. A., and Moore, W. M. (1991) Phosphor-amidon blocks the pressor activity of big endothelin (1–39) and lowers blood pressure in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 17(Suppl. 7): S29—S33.Google Scholar
  26. 26.
    Sogabe, K., Nirei, H., Shoubo, M., Nomoto, A., Ao, S., Notsu, Y., and Ono, T. (1992) Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J. Pharmacol. Exp. Ther. 264:1040–1044.Google Scholar
  27. 27.
    Nishikibe, M., Tsuchida, S., Okada, M., Fukuroda, R., Shimamoto, K., and Yano, M. (1993) Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 52: 717–724.PubMedCrossRefGoogle Scholar
  28. 28.
    Ohlstein, E. H., Douglas, S. A., Ezekiel, M., and Gellai, M. (1993) Anti-hypertensive effects of the endothelin antagonist BQ-123 in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 22(Suppl. 8 ): 5321 — S324.Google Scholar
  29. 29.
    Ohlstein, E. H., Nambi, P., Douglas, S. A., Edwards, R. M., Gellai, M., Lago, A., Leber, J. D., Cousins, R. D., Gao, A., Frazee, J. S., Peishoff, C. E., Bean, J. W., Eggleston, D. S., Elshourbagy, N. A., Kumar, C., Lee, J. A., Brooks, D. P., Ruffolo, R. R., Jr., Feuerstein, G. Z., Weinstock, J., Gleason, J. G., and Elliott, J. D. (1994) SB 209670, rationally designed potent nonpeptide endothelin receptor antagonist. Proc. Natl. Acad. Sci. USA 9: 8052–8056.Google Scholar
  30. 30.
    Douglas, S. A., Gellai, M., Ezekiel, M., and Ohlstein, E. H. (1994) BQ123, a selective endothelin (ETA) receptor antagonist, lowers blood pressure in different models of hypertension. J. Hypertens 12: 561–567.PubMedCrossRefGoogle Scholar
  31. 31.
    Verma, S., Bhanot, S. and McNeill, J. H. (1995) Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am. J. Physiol 269: H2017 — H2021.PubMedGoogle Scholar
  32. 32.
    Stasch, J. P., Hirth-Dietrich, C., Frobel, K., and Wegner, M. (1995) Prolonged endothelin blockade reduces hypertension and cardiac hypertrophy in SHR-SP. J. Cardiovasc. Pharmacol. 26(Suppl. 3 ): 5436 — S438.Google Scholar
  33. 33.
    Schiffrin, E. L., Sventek, P., Li, J.-S., Turgeon, A., and Reudelhuber, T. (1995) Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br. J. Pharmacol. 115:1377–1381.Google Scholar
  34. 34.
    Bird, J. E., Moreland, S., Waldron, T. L., and Powell, J. R. (1995) Anti-hypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 25: 1191–1195.Google Scholar
  35. 35.
    Li, J.-S. and Schiffrin, E. L. (1995) Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 25(part 1 ): 495–500.Google Scholar
  36. 36.
    Clozel, M. and Breu, V. (1996) The role of ET(B) receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ET(B) receptor antagonist Ro 46–8443. FEBS Lett. 383: 42–45.PubMedCrossRefGoogle Scholar
  37. 37.
    Donckier, J., Stoleru, L., Hayashida, W., Van Mechelen, H., Selvais, P., Galanti, L., Clozel, J.-P., Ketelslegers, J.-M., and Pouleur, H. (1995) Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 92: 106–113.Google Scholar
  38. 38.
    Kiowski, W., Sutsch, G., Hunziker, P., Muller, P., Kim, J., Oechslin, E., Schmitt, R., Jones, R., and Bertel, O. (1995) Evidence for endothelin1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732–736.Google Scholar
  39. 39.
    Haynes, W. G. and Webb, D. J. (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852–854.PubMedCrossRefGoogle Scholar
  40. 40.
    Haynes, W. G., Ferro, C. J., O’Kane, K. P., Somerville, D., Lomax, C. C., and Webb, D. J. (1996) Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93:1860–1870.Google Scholar
  41. 41.
    Freed, M. I., Thompson, K. A., Wilson, D. E., Ohlstein, E. H., Dennis, M., and Jorkasky, D. K. (1996) Effects of SB 217242, a non-selective endothelin (ET-A and ET-B receptor antagonist, in healthy humans. J. Am. Soc. Nephrol. 7, 1561.Google Scholar
  42. 42.
    Wei, C. M., Lerman, A., Rodeheffer, R J., McGregor, C. G. A., Brandt, R. R., Wright, S., Kao, P. C., Edwards, W. D Burnett, J. C., and Heublein, D. M. (1994) Endothelin in human congestive heart failure. Circulation 89: 1580–1586Google Scholar
  43. 43.
    Pacher, R., Stanek, B., Hulsmann, M., Koller-Strametz, J., Berger, R., Schuller, M., Hartter, E., Ogris, E., Frey, B., Heinz, G., and Maurer, G. (1996) Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol 27: 633–641.PubMedCrossRefGoogle Scholar
  44. 44.
    Omland, T., Lie, R. T., Aakvaag, A., Aarsland, T., and Dickstein, K. (1994) Plasma endothelin determinations as a prognostic indication of one year mortality after acute myocardial infarction. Circulation 89: 1573–1579.Google Scholar
  45. 45.
    Krum, H. and Itescu, S. (1994) Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects. Clin. Exp. Pharmacol. Physiol 21: 311–313.PubMedCrossRefGoogle Scholar
  46. 46.
    Cavero, P. G., Miller, W. L., Heublein, D. M., Margulies, K. B., and Burnett, J. C. (1990) Endothelin in experimental congestive heart failure in the anesthetized dog. Am. J. Physiol. 259:F312—F317.Google Scholar
  47. 47.
    Yorikane, R., Sakai, S., Miyauchi, T., Sakurai, T., Sugishita, Y., and Goto, K. (1993) Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett. 332: 31–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Miyauchi, T., Sakai, S., Ihara, M., Kasuya, Y., Yamaguchi, I., Goto, K., and Sugishita, Y. (1995) Increased endothelin-1 binding sites in the cardiac membranes in rats with chronic heart failure. J. Cardiovasc. Pharmacol 26 (Suppl. 3): S448–5451.PubMedGoogle Scholar
  49. 49.
    Yamazaki, T., Komuro, I., Kudoh, S., Zou, Y., Shiojima, I., Hiroi, Y., Mizuno, T., Maemura, K., Kurihara, H., Aikawa, R., Takano, H., and Yazaki, Y. (1996) Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J. Biol. Chem 271: 3221–3228.PubMedCrossRefGoogle Scholar
  50. 50.
    Ito, H., Hiroe, M., Hirata, Y., Fujisaki, H., Adachi, S., Akimoto, H., Ohta, Y., and Marumo, F. (1994) Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89: 2198–2203.PubMedCrossRefGoogle Scholar
  51. 51.
    Teerlink, J. R., Loffler, B.-M., Hess, P., Maire, J.-P., Clozel, M., and Clozel, J.-P. (1994) Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47–0203 (bosentan). Circulation 90: 2510–2518.PubMedCrossRefGoogle Scholar
  52. 52.
    Sakai, S., Miyauchi, T., Kobayashi, M., Yamaguchi, I., Goto, K., and Sugishita, Y. (1996) Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353–355.PubMedCrossRefGoogle Scholar
  53. 53.
    Shimoyama, H., Sabbah, H. N., Borzak, S., Tanimura, M., Shevlyagin, S., Scicli, G., and Goldstein, S. (1996) Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 94: 779–784.PubMedCrossRefGoogle Scholar
  54. 54.
    Tohmo, H., Karanko, M., Korpilahti, K., Scheinin, M., Viinamaki, O., and Neuvonen, P. (1994) Enalaprilat in acute intractable heart failure after myocardial infarction: a prospective, consecutive sample, before and after. Crit. Care Med 22: 965–973.PubMedCrossRefGoogle Scholar
  55. 55.
    Davidson, N. C., Coutie, W. J., Webb, D. J., and Struthers, A. D. (1996) Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 75: 576–581.PubMedCrossRefGoogle Scholar
  56. 56.
    Grenier, O., Pousset, F., Isnard, R., Kalotka, H., Carayon, A., Maistre, G., Lechat, P., Guerot, C., Thomas, D., and Komajda, M. (1996) Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure. Cardiovasc. Drugs Ther 10: 561–565.PubMedCrossRefGoogle Scholar
  57. 57.
    Krum, H., Gu, A., Wilshire-Clement, M., Sackner-Bernstein, J., Goldsmith, R., Medina, N., Yushak, M., Miller, M., and Packer, M. (1996) Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am. Heart J 131: 337–341.PubMedCrossRefGoogle Scholar
  58. 58.
    Martin-Nizard, F., Houssaini, H. S., Lestavel-Delattre, S., Duriez, P., and Fruchart, J.-C. (1991) Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett. 293: 127–130.PubMedCrossRefGoogle Scholar
  59. 59.
    Salomone, O. A., Elliott, P. M., Calvino, R., Holt, D., and Kaski, J. C. (1996) Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J. Am. Coll. Cardiol 28: 14–19.PubMedCrossRefGoogle Scholar
  60. 60.
    Ihling, C., Gobel, H. R., Lippoldt, A., Wessels, S., Paul, M., Schaefer, H. E., and Zeiher, A. M. (1996) Endothelin-1-like immunoreactivity in human atherosclerotic coronary tissue: a detailed analysis of the cellular distribution of endothelin-1. J. Pathol 179: 303–308.PubMedCrossRefGoogle Scholar
  61. 61.
    Mangiafico, R. A., Malatino, L. S., Santonocito, M., Spada, R. S., Polizzi, G., and Tamburino, G. (1996) Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. Int. Angiol 15: 240–244.PubMedGoogle Scholar
  62. 62.
    Lerman, A., Webster, M. W., Chesebro, J. H., Edwards, W. D., Wei, C. M., Fuster, V., and Burnett, J. C., Jr. (1993) Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation 88: 2923–2928.PubMedCrossRefGoogle Scholar
  63. 63.
    Azuma, H., Hamasaki, H., Niimi, Y., Terada, T., and Matsubara, O. (1994) Role of endothelin-1 in neointima formation after endothelial removal in rabbit carotid arteries. Am. J. Physiol 267: H2259 — H2267.PubMedGoogle Scholar
  64. 64.
    Wang, X., Douglas, S. A., and Ohlstein, E. H. (1996) The use of quantitative RT-PCR to demonstrate the increased expression of endothelinrelated mRNAs following angioplasty-induced neointima formation in the rat. Circ. Res 78: 322–328.Google Scholar
  65. 65.
    Lopez, J. A. G., Armstrong, M. L., Piegors, D. J., and Heistad, D. D. (1990) Vascular responses to endothelin-1 in atherosclerotic primates. Artheriosclerosis 10: 11–13.Google Scholar
  66. 66.
    Prat, L., Carri6, I., Roca, M., Riambau, V., Berné, L., Estorch, M., Ferrer, I., and Garcia, C. (1993) Polyclonal ’ 11In-IgG, 1251-LDL and 1251-endothelin-1 accumulation in experimental arterial wall injury. Eur. J. Nucl. Med 20: 1141–1145.PubMedGoogle Scholar
  67. 67.
    Dashwood, M., Barker, S. G. E., Muddle, J. R., Yacoub, M. H., and Martin, J. F. (1993) [125I]-Endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: a possible role for endothelin in intimai hyperplasia and atherosclerosis. J. Cardiovasc. Pharmacol 22(Suppl 8):S343—S347.Google Scholar
  68. 68.
    Dashwood, M. R., Allen, S. P., Luu, T. N., and Muddle, J. R. (1994) The effect of the ETA receptor antagonist, FR 139317, on [1251]-ET-1 binding to the atherosclerotic human coronary artery. Br. J. Pharmacol 112: 386–389.PubMedCrossRefGoogle Scholar
  69. 69.
    Kurata, C., Callahan, R. J., Molea, N., Wilkinson, R., Fischman, A. J., and Strauss, H. W. (1995) Localization of [125I] endothelin-1 in injured aorta of rabbits. Eur. J. Pharmacol 293: 109–114.PubMedCrossRefGoogle Scholar
  70. 70.
    Bacon, C. R., Cary, N. R., and Davenport, A. P. (1995) Distribution of endothelin receptors in atherosclerotic human coronary arteries. J. Cardiovasc. Pharmacol. 26(Suppl. 3 ): S439 — S441.Google Scholar
  71. 71.
    Douglas, S. A. and Ohlstein, E. H. (1993) Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. J. Cardiovasc. Pharmacol. 22(Suppl. 8 ): S371 — S373.Google Scholar
  72. 72.
    Trachtenberg, J. D., Sun, S., Choi, E. T., Callow, A. D., and Ryan, U. S. (1993) Effect of endothelin-1 infusion on the development of intimal hyperplasia after balloon catheter injury. J. Cardiovasc. Pharmacol. 22 (Suppl. 8 ): 5355–359.Google Scholar
  73. 73.
    Douglas, S. A., Vickery-Clark, L. M., Storer, B. L., Hart, T., Louden, C., Elliott, J. D., and Ohlstein, E. H. (1994) A role for endogenous endothelin-1 in neointima formation following rat carotid artery balloon angioplasty: antiproliferative effects of the non-peptide endothelin receptor antagonist SB 209670. Circ. Res 75: 190–197.PubMedCrossRefGoogle Scholar
  74. 74.
    Ferrer, P., Valentine, M., Jenkins-West, T., Weber, H., Goller, N. L., Durham, S. K., Molloy, C. J., and Moreland, S. (1995) Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J. Cardiovasc. Pharmacol 26: 908–915.Google Scholar
  75. 75.
    Kowala, M. C., Rose, P. M., Stein, P. D., Goller, N., Recce, R., Beyer, S., Valentine, M., Barton, D., and Durham, S. K. (1995) Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am. J. Pathol 146: 819–826.PubMedGoogle Scholar
  76. 76.
    Larkin, S. W., Clarke, J. G., Keogh, B. E., Araujo, L., Rhodes, C., Davies, G. J., Taylor, K. M., and Maseri, A. (1989) Intracoronary endothelin induces myocardial ischemia by small vessel constriction in the dog. Am. J. Cardiol 64: 956–958.Google Scholar
  77. 77.
    Lee, S.-Y., Lee, C. Y., Chen, Y. M., and Kochva, E. (1986) Coronary vasospasm as the primary cause of death due to the venom of the burrowing asp, Atractaspis engaddensis. Toxicon 24: 285–291.PubMedCrossRefGoogle Scholar
  78. 78.
    Setsuta, K., Seino, Y., Tomita, Y., Nejima, J., Takano, T., and Hayakawa, H. (1995) Origin and pathophysiological role of increased plasma endothelin-1 in patients with acute myocardial infarction. Angiology 46: 557–565.Google Scholar
  79. 79.
    Tonnessen, T., Giaid, A., Saleh, D., Naess, P. A., Yanagisawa, M., and Cristensen, G. (1995) Increased in vivo expression and production of endothelin1 by porcine cardiomyocytes subjected to ischemia. Circ. Res 76: 767–772.Google Scholar
  80. 80.
    Kyriakides, Z. S., Markianos, M., Iliodromitis, E. K., and Kremastinos, D. T. (1995) Vein plasma endothelin-1 and cyclic GMP increase during coronary angioplasty is related to myocardial ischaemia. Eur. Heart J 16: 894–898.PubMedGoogle Scholar
  81. 81.
    Franco-Cereceda, A., Grip, L. G., Moor, E., Velander, M., Liska, J., and Lundberg, J. M. (1995) Influence of percutaneous transluminal coronary angioplasty on cardiac release of endothelin, neuropeptide Y and noradrenaline. Int. J. Cardiol 48: 231–233.Google Scholar
  82. 82.
    Nelson, R. A., Burke, S. E., and Opgenorth, T. (1994) Endothelin receptor antagonist fr 139317 reduces infarct size in a rabbit coronary artery occlusion model. FASEB J. 8: A854.Google Scholar
  83. 83.
    Lee, J. Y., Warner, R. B., Adler, A. L., and Opgenorth, T. J. (1994) The ETA receptor antagonist FR 139317 reduces myocardial infarction induced by coronary artery occlusion and reperfusion in the rat. FASEB J. 8: A854.Google Scholar
  84. 84.
    Wang, Q. D., Li, X. S., and Pernow, J. (1995) The nonpeptide endothelin receptor antagonist bosentan enhances myocardial recovery and endothelial function during reperfusion of the ischemic rat heart. J. Cardiovasc. Pharmacol 26 (Suppl. 3): S445–S447.PubMedCrossRefGoogle Scholar
  85. 85.
    McMurdo, L., Thiemermann, C., and Vane, J. R. (1994) The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischemia and reperfusion. Br. J. Pharmacol 112: 75–80.PubMedCrossRefGoogle Scholar
  86. 86.
    Vitola, J. V., Forman, M. B., Holsinger, J. P., Kawana, M., Atkinson, J. B., Quertermous, T., Jackson, E. K., and Murray, J. J. (1996) Role of endothelin in a rabbit model of acute myocardial infarction—effects of receptor antagonists. J. Cardiovasc. Pharmacol 28: 774–783.PubMedCrossRefGoogle Scholar
  87. 87.
    Erikson, J. M. and Velasco, C. E. (1996) Endothelin-1 and myocardial preconditioning. Am. Heart J 132: 84–90.PubMedCrossRefGoogle Scholar
  88. 88.
    Mertz, T. E., McClanahan, T. B., Flynn, M. A., Juneau, P., Reynolds, E. E., Hallak, H., Bradford, L., and Gallagher, K. P. (1996) EndothelinA receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs. J. Pharmacol. Exp. Ther 278: 42–49.PubMedGoogle Scholar
  89. 89.
    Wang, Q. D., Li, X. S., Lundberg, J. M., and Pernow, J. (1995) Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc. Res 29: 805–812.PubMedGoogle Scholar
  90. 90.
    Grover, G. J., Dzwonczyk, S., and Parham, C. S. (1993) The endothelin1 receptor antagonist BQ123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc. Res. 27: 1613–1618.Google Scholar
  91. 91.
    Kojima, M., Kusumoto, K., Fujiwara, S., Watanabe, T., and Fujino, M. (1995) Role of endogenous endothelin in the extension of myocardial infarct size studies with the endothelin receptor antagonist, TAK-044. J. Cardiovasc. Pharmacol 26 (Suppl. 3), S365–S368.PubMedGoogle Scholar
  92. 92.
    Watanabe, T., Awane, Y., Ikeda, S., Fujiwara, S., Kubo, K., Kikuchi, T., Kusumoto, K., Wakimasu, M., and Fujino, M. (1995) Pharmacology of a non-selective ETA and ETB receptor antagonist TAK-044, and the inhibition of myocardial infarct size in rats. Br. J. Pharmacol 114: 949–954.PubMedCrossRefGoogle Scholar
  93. 93.
    Illing, B., Horn, M., Han, H., Hahn, S., Bureik, P., Ertl, G., and Neubauer, S. (1996) Protective effect of the specific endothelin-1 antagonist BQ610 on mechanical function and energy metabolism during ischemia/ reperfusion injury in isolated perfused rat hearts. J. Cardiovasc. Pharmacol 27: 487–494.Google Scholar
  94. 94.
    Garjani, A., Wainwright, C.L., Zeitlin, I. J., Wilson, C., and Slee, S.-J. (1995) Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischemia arrhythmias in anesthetized rats. J. Cardiovasc. Pharmacol 25: 634–642.Google Scholar
  95. 95.
    Omland, T., Bonarjee, V.V., Lie, R.T., and Caidahl, K. (1995) Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am. J. Cardiol 76: 230–235.PubMedCrossRefGoogle Scholar
  96. 96.
    Asano, T., Ikegaki, I., Suzuki, Y., Satoh, S.-I., and Shibuya, M. (1989) Endothelin and the production of cerebral vasospasm in dogs. Biochem. Biophys. Res. Commun 159: 1345–1351.PubMedCrossRefGoogle Scholar
  97. 97.
    Ohlstein, E. H. and Storer, B. L. (1992) Oxyhemoglobin stimulated endothelin production in cultured endothelial cells. J. Neurosurg 77: 274–278.PubMedCrossRefGoogle Scholar
  98. 98.
    Masaoka, H., Suzuki, R., Hirata, Y., Emori, T., Marumo, F., and Hirakawa, K. (1989) Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 2: 1402.PubMedCrossRefGoogle Scholar
  99. 99.
    Wang, X., Zhu, C., Zhang, G., and Lu, Y. (1995) Changes of endothelin during cerebral vasospasm after experimental subarachnoid hemorrhage. Chin. Med. J. Engl 108: 586–590.PubMedGoogle Scholar
  100. 100.
    Seifert, V., Loffler, B. M., Zimmermann, M., Roux, S., and Stolke, D. (1995) Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J. Neurosurg. 82:55–62.Google Scholar
  101. 101.
    Papadopoulos, S. M., Gilbert, L. L., Webb, R. C., and D’Amato, C. J. (1990) Characterization of contractile responses to endothelin in human cerebral arteries: implications for cerebral vasospasm. Neurosurgery 26: 810–815.Google Scholar
  102. 102.
    Zimmerman, M., Seifert, V., Loffler, B. M., Stolke, D., and Stenzel, W. (1996) Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47–0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery 38: 115–120.Google Scholar
  103. 103.
    Itoh, S., Sasaki, T., Asai, A., and Kuchino, Y. (1994) Prevention of delayed vasospasm by an endothelin ETA receptor antagonist BQ123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J. Neurosurg. 81: 759–764.Google Scholar
  104. 104.
    Matsumura, Y., Ikegawa, R., Suzuki, Y., Takaoka, M., Uchida, T., Kido, H., Shinyama, H., Hayashi, K., Watanabe, M., and Morimoto, S. (1991) Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci. 49: 841–848.Google Scholar
  105. 105.
    Itoh, S., Sasaki, T., Ide, K., Ishikawa, K., Nishikibe, M., and Yano, M. (1993) A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental vasospasm in dogs. Biochem. Biophys. Res. Commun 195: 969–975.PubMedCrossRefGoogle Scholar
  106. 106.
    Clozel, M. and Watanabe, H. (1994) BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci. 52: 825–834.CrossRefGoogle Scholar
  107. 107.
    Foley, P. L., Caner, H. H., Kassell, N. F., and Lee, K. S. (1994) Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 34: 108–113.Google Scholar
  108. 108.
    Hino, A., Weir, B. K. A., Macdonald, R. L., Thisted, R. A., Kim, C.-J., and Johns, L. M. (1995) Prospective, randomized, double-blind trial of BQ123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. J. Neurosurg 83: 503–509.PubMedCrossRefGoogle Scholar
  109. 109.
    Cosentino, F., Mcmahon, E. G., Carter, J. S., and Katusic, Z. S. (1993) Effect of endothelinA receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. J. Cardiovasc. Pharmacol. 22(Suppl. 8): S332—S335.Google Scholar
  110. 110.
    Caner, H. H Kwan, A. L., Arthur, A., Jeng, A. Y., Lappe, R. W., Kassell, N. F., and Lee, K. S. (1996) Systemic administration of an inhibitor of endothelin converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. J. Neurosurg 85: 917–922Google Scholar
  111. 111.
    Clozel, M., Breu, V., Gray, G. A., and Löffler, B. M. (1993) In vivo pharmacology of Ro 46–2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J. Cardiovasc. Pharmacol 22(Suppl 8): S377—S379.Google Scholar
  112. 112.
    Nirei, H., Hamada, K., Shoubo, M., Sogabe, K., Notsu, Y., and Ono, T. (1993) An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci. 52: 1869–1874.Google Scholar
  113. 113.
    Roux, S., Loftier, B. M., Gray, G. A., Sprecher, U., Clozel, M., and Clozel, J. P. (1995) The role of endothelin in experimental cerebral vasospasm. Neurosurgery 37: 78–86.PubMedCrossRefGoogle Scholar
  114. 114.
    Shigeno, T., Clozel, M., Sakai, S., Saito, A., and Goto, K. (1995) The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 37: 87–90.Google Scholar
  115. 115.
    Zuccarello, M., Soattin, G. B., Lewis, A., Breu, V., Hallak, H., and Rapoport, R. M. (1996) Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J. Neurosurg 84: 503–507.Google Scholar
  116. 116.
    Willette, R. N., Zhang, H., Mitchell, M. P., Sauermelch, C. F., Ohlstein, E. H., and Sulpizio, A. C. (1994) Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke 25: 2450–2456.Google Scholar
  117. 117.
    Willette, R. N., Feuerstein, G. Z., and Barone, F. C. (1995) Endothelin in the central nervous system, in Endothelin Receptors: From the Gene to the Human ( Ruffolo, R. R., Jr., ed.), CRC, Boca Raton, FL, pp. 187–213.Google Scholar
  118. 118.
    Barone, F C., Willette, R. N., Yue, T.-L., and Feuerstein, G. (1995) Therapeutic effects of endothelin receptor antagonists in stroke. Neurol. Res 17:259–264.Google Scholar
  119. 119.
    Sharkey, J. and Butcher, S. P. (1995) Characterization of an experimental model of stroke produced by intracerebral microinjection of endothelin1 adjacent to the rat middle cerebral artery. J. Neurosci. Methods 60: 125–131.Google Scholar
  120. 120.
    Agnati, L. F., Zoli, M., Kurosawa, M., Benfenati, F., Biagini, G., Zini, I., Hallstrom, A., Ungerstedt, U., Toffano, G., and Fuxe, K. (1991) A new model of focal brain ischemia based on the intracerebral injection of endothelin-l. Ital. J. Neurol. Sci. 12(3 Suppl. 11 ): 49–53.Google Scholar
  121. 121.
    Ziv, I., Fleminger, G., Djaldetti, R., Achiron, A., Melamed, E., and Sokolovsky, M. (1992) Increased plasma endothelin-1 in acute ischemic stroke. Stroke 23: 1014–1016.Google Scholar
  122. 122.
    Wei, G. Z., Zhang, J., Sheng, S. L., Ai, H. X., Ma, J. C., and Lui, H. B. (1993) Increased plasma endothelin-1 concentration in patients with acute cerebral infarction and actions of endothelin-1 on pial arterioles of rat. Chin. Med. J. Engl 106: 917–921.Google Scholar
  123. 123.
    Giuffrida, R., Bellomo, M., Polizzi, G., and Malatino, L. S. (1992) Ischemia-induced changes in he immunoreactivity for endothelin and other vasoactive peptides in the brain of the Mongolian gerbil. J. Cardiovasc. Pharmacol 20 (Suppl. 12): S41 - S44.PubMedCrossRefGoogle Scholar
  124. 124.
    Willette, R. N., Ohlstein, E. H., Pullen, M., Sauermelch, C. F., Cohen, A., and Nambi, P. (1993) Transient forebrain ischemia alters acutely endothelin receptor density and immunoreactivity in gerbil brain. Life Sci. 52: 35–40.PubMedCrossRefGoogle Scholar
  125. 125.
    Viossat, I Duverger, D., Chapelat, M., Pirotzky, E., Chabrier, P. E., and Braquet, P. (1993) Elevated tissue endothelin content during focal cerebral ischemia in the rat. J. Cardiovasc. Pharmacol 22(Suppl 8):S306–S309.Google Scholar
  126. 126.
    Barone, F. C., Globus, M. Y., Price, W. J., White, R. F., Storer, B. L., Feuerstein, G. Z., Busto, R., and Ohlstein, E. H. (1994) Endothelin levels increase in rat focal and global ischemia. J. Cereb. Blood Flow Metab 14: 337–342.PubMedCrossRefGoogle Scholar
  127. 127.
    Yamashita, K., Kataoka, Y., Niwa, M., Shigematsu, K., Himeno, A., Koizumi, S., and Taniyama, K. (1993) Increased production of endothelins in the hippocampus of stroke-prone spontaneously hypertensive rats following transient forebrain ischemia: histochemical evidence. Cell Mol. Neurobiol. 13: 15–23.Google Scholar
  128. 128.
    Kohzuki, M., Onodera, H., Yasujima, M., Itoyama, Y., Kanazawa, M., Sato, T., and Abe, K. (1995) Endothelin receptors in ischemic rat brain and Alzheimer brain. J. Cardiovasc. Pharmacol. 26(Suppl. 3): S329–S331.Google Scholar
  129. 129.
    Feuerstein, G. Z., Gu, J.-L., Ohlstein, E. H., Barone, F. C., and Yue, T. L. (1994) Selective endothelin receptor (ETA) antagonist is neuroprotective in gerbil transient forebrain ischemia. Stroke 25: 264.Google Scholar
  130. 130.
    Barone, F. C., White, R. F., Elliott, J. D., Feuerstein, G. Z., and Ohlstein, E. H. (1995) The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J. Cardiovasc. Pharmacol. 26(Suppl. 3 ): S404 - S407.Google Scholar
  131. 131.
    Patel, T. R. and McCulloch, J. (1996) Failure of an endothelin antagonist to modify hypoperfusion after transient global ischaemia in the rat. J. Cereb. Blood Flow Metab 16: 490–499.PubMedCrossRefGoogle Scholar
  132. 132.
    Patel, T. R., McAuley, M. A., and McCulloch, J. (1994) Effects on feline pial arterioles in situ of bosentan, a non-peptide, endothelin receptor antagonist. Eur. J. Pharmacol 260: 65–71.PubMedCrossRefGoogle Scholar
  133. 133.
    Patel, T. R., Galbraith, S., Graham, D. I., Hallak, H., Doherty, A. M., and McCulloch, J. (1996) Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J. Cereb. Blood Flow Metab 16: 950–958.PubMedCrossRefGoogle Scholar
  134. 134.
    Wilkes, B. M., Susin, M., and Mento, P. F. (1993) Localization of endothelin-1-like immunoreactivity in human placenta. J. Histochem. Cytochem 41: 535–541.PubMedCrossRefGoogle Scholar
  135. 135.
    Nova, A., Sibai, B. M., Barton, J. R., Mercer, B. M., and Mitchell, M. D. (1991) Maternal plasma level of endothelin is increased in preeclampsia. Am. J. Obstet. Gynecol 165: 724–727.PubMedGoogle Scholar
  136. 136.
    Benigni, A., Orisio, S., Gaspari, F., Frusca, T., Amuso, G., and Remuzzi, G. (1992) Evidence against a pathogenetic role for endothelin in pre-eclampsia. Br. J. Obstet. Gynecol 99: 798–802.CrossRefGoogle Scholar
  137. 137.
    Cervar, M., Kainer, F., Jones, C. J., and Desoye, G. (1996) Altered release of endothelin-1,2 and thromboxane B2 from trophoblastic cells in pre-eclampsia. Eur. J. Clin. Invest 26: 30–37.PubMedCrossRefGoogle Scholar
  138. 138.
    McMahon, L. P., Redman, C. W., and Firth, J. D. (1993) Expression of the three endothelin genes and plasma levels of endothelin in pre-eclampsia and normal gestations. Clin. Sci. Colch 85: 417–424.PubMedGoogle Scholar
  139. 139.
    Schiff, E., Galron, R., Ben-Baruch, G., Mashiach, S., and Sokolovsky, M. (1993) Endothelin-1 receptors on the human placenta and fetal membranes: evidence for different binding properties in pre-eclamptic pregnancies. Gynecol. Endocrinol 7: 67–72.PubMedCrossRefGoogle Scholar
  140. 140.
    Cervar, M., Kainer, F., and Desoye, G. (1995) Pre-eclampsia and gestational age differently alter binding of endothelin-1 to placental and trophoblast membrane preparations. Mol. Cell Endocrinol. 110: 65–71.Google Scholar
  141. 141.
    Vedernikov, Y. P., Belfort, M. A., Saade, G. R., and Moise, K. J., Jr. (1995) Pre-eclampsia does not alter the response to endothelin-1 in human omental artery. J. Cardiovasc. Pharmacol. 26(Suppl. 3): S233—S235.Google Scholar
  142. 142.
    Morel, D. R., Lacroix, J. S., Hemsen, A., Steinig, D. A., Pittet, J-F., and Lundberg, J. M. (1989) Increased plasma and pulmonary lymph levels of endothelin during endotoxin shock. Eur. J. Pharmacol 167: 427, 428.Google Scholar
  143. 143.
    Nambi, P., Pullen, M., Slivjak, M. J., Ohlstein, E. H., Storer, B., and Smith, E. F., III (1994) Endotoxin-mediated changes in plasma endothelin concentrations, renal endothelin receptor and renal function. Pharmacology 48: 147–156.PubMedCrossRefGoogle Scholar
  144. 144.
    Smits, P., Hofman, H., Rosmalen, F., Wollersheim, H., and Thien, T. (1991) Endothelin-1 in patients with Raynaud’s phenomenon. Lancet 337: 236.PubMedCrossRefGoogle Scholar
  145. 145.
    Farkkila, M., Palo, J., Saijonmaa, O., and Fyhrquist, F. (1992) Raised plasma endothelin during acute migraine attack. Cephalalgia 12: 383-384.Google Scholar
  146. 146.
    Brandli, P., Loffler, B. M., Breu, V., Osterwalder, R., Maire, J. P., and Clozel, M. (1996) Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64:315–322.Google Scholar
  147. 147.
    Aoki, T., Kojima, T., Ono, A., Unishi, G., Yoshijima, S., Kameda-Hayashi, N., Yamamoto, C., Hirata, Y., and Kobayashi, Y. (1994) Circulating endothelin-1 levels in patients with bronchial asthma. Ann. Allergy 73: 365–369.PubMedGoogle Scholar
  148. 148.
    Springall, D. R., Howarth, P. H Counihan, H., Djukanovic, R., Holgate, S. T., and Polak, J. M. (1991) Endothelin immunoreactivity of airway epithelium in asthmatic patients. Lancet 337: 697–701Google Scholar
  149. 149.
    Vittori, E., Marini, M., Fasoli, A., De Franchis, R., and Mattoli, S. (1992) Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids. Am. Rev. Respir. Dis 146: 1320–1325.PubMedGoogle Scholar
  150. 150.
    Ackerman, V., Carpi, S., Bellini, A., Vassalli, G., Marini, M., and Mattoli, S. (1995) Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1. J. Allergy Clin. Immunol 96: 618–627.PubMedCrossRefGoogle Scholar
  151. 151.
    Knott, P. G., D’Aprile, A. C., Henry, P. J., Hay, D. W., and Goldie, R. G. (1995) Receptors for endothelin-1 in asthmatic human peripheral lung. Br. J. Pharmacol 114: 1–3.PubMedCrossRefGoogle Scholar
  152. 152.
    Chanez, P., Vignola, A. M., Albat, B., Springall, D. R., Polak, J. M., Godard, P., and Bousquet, J. (1996) Involvement of endothelin in mononuclear phagocyte inflammation in asthma. J. Allergy Clin. Immunol 98: 412–420.Google Scholar
  153. 153.
    Riccio, M. M., Reynolds, C. J., Hay, D. W., and Proud, D. (1995) Effects of intranasal administration of endothelin-1 to allergic and nonallergic individuals. Am. J. Respir. Crit. Care Med 152: 1757–1764.PubMedGoogle Scholar
  154. 154.
    Uchida, Y., Jun, T., Ninomiya, H., Ohse, H., Hasegawa, S., Nomura, A., Sakamoto, T., Sardessai, M. S., and Hirata, F. (1996) Involvement of endothelins in immediate and late asthmatic responses of guinea pigs. J. Pharmacol. Exp. Ther 277: 1622–1629.PubMedGoogle Scholar
  155. 155.
    Goerre, S., Wenk, M., Bartsch, P., Luscher, T. F., Niroomand, F., Hohenhaus, E., Oelz, O., and Reinhart, W. H. (1995) Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation 90: 359–364.CrossRefGoogle Scholar
  156. 156.
    Mitaka, C., Hirata, Y., Nagura, T., Tsunoda, Y., and Amaha, K. (1993) Circulating endothelin-1 concentrations in acute respiratory failure. Chest 104: 476–480.PubMedCrossRefGoogle Scholar
  157. 157.
    Ishikawa, S., Miyauchi, T., Ueno, H., Ushinohama, H., Sagawa, K., Fusazaki, N., Sunagawa, H., Honda, S., Sakai, S., and Yamaguchi, I. (1995) Influence of pulmonary blood pressure and flow on endothelin-1 production in humans. J. Cardiovasc. Pharmacol. 26(Suppl. 3 ): S429 — S433.Google Scholar
  158. 158.
    Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P., and Stewart, D. J. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl. J. Med. 328: 1732–1739.Google Scholar
  159. 159.
    Stelzner, T. J., O’Brien, R. F., Yanagisawa, M., Sakurai, T., Sato, K., Webb, S., Zamora, M., McMurtry, I. F., and Fisher, J. H. (1992) Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am. J. Physiol 262: L614 – L618.PubMedGoogle Scholar
  160. 160.
    Sakai, S., Miyauchi, T., Sakurai, T., Yamaguchi, I., Kobayashi, M., Goto, K., and Sugishita, Y. (1996) Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. J. Am. Coll. Cardiol. 28: 1580–1588.Google Scholar
  161. 161.
    MacLean, M. R., McCulloch, K. M., and Baird, M. (1995) Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6c and on inherent tone in rat pulmonary arteries. J. Cardiovasc. Pharmacol 26: 822–830.PubMedCrossRefGoogle Scholar
  162. 162.
    Stewart, A. G., Grigoriadis, G., and Harris, T. (1994) Mitogenic actions of endothelin-1 and epidermal growth factor in cultured airway smooth muscle. Clin. Exp. Pharmacol. Physiol 21: 277–285.PubMedCrossRefGoogle Scholar
  163. 163.
    Panettieri, R. A., Jr., Goldie, R. G., Rigby, P. J., Eszterhas, A. J., and Hay, D. W. (1996) Endothelin-1-induced potentiation of human airway smooth muscle proliferation: an ETA receptor-mediated phenomenon. Br. J. Pharmacol 118: 191–197.PubMedCrossRefGoogle Scholar
  164. 164.
    Marini, M., Carpi, S., Bellini, A., Patalano, F., and Mattoli, S. (1996) Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem. Biophys. Res. Commun 220: 896–899.PubMedCrossRefGoogle Scholar
  165. 165.
    Mansoor, A. M., Honda, M., Saida, K., Ishinaga, Y., Kuramochi, T., Maeda, A., Takabatake, T., and Mitsui, Y. (1995) Endothelin-induced collagen remodeling in experimental pulmonary hypertension. Biochem. Biophys. Res. Commun 215: 981–986.PubMedCrossRefGoogle Scholar
  166. 166.
    Okada, M., Yamashita, C., Okada, M., and Okada, K. (1995) Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation 92: 114–119.PubMedCrossRefGoogle Scholar
  167. 167.
    Wagner, O. F., Vierhapper, H., Gasic, S., Nowotny, P., and Waldhausl, W. (1992) Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur. J. Clin. Invest 22: 277–282.PubMedCrossRefGoogle Scholar
  168. 168.
    Kaasjager, K. A. H., Shaw, S., Koomans, H. A., and Rabelink, T. J. (1997) Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans. J. Am. Soc. Nephrol 8: 32–39.PubMedGoogle Scholar
  169. 169.
    Tomita, K., Ujiie, K., Nakanishi, T., Tomura, S., Matsuda, O., Ando, K., Shichiri, M., Hirata, Y., and Marumo, F. (1989) Plasma ET levels in patients with acute renal failure. Eur. J. Med 32: 1127.Google Scholar
  170. 170.
    Sandok, E. K., Lerman, A., Stingo, A. J., Perrella, M. A., Gloviczki, P., and Burnett, J. C., Jr. (1992) Endothelin in a model of acute ischemic renal dysfunction: modulating action of atrial natriuretic factor. J. Am. Soc. Nephrol 3: 196–202.PubMedGoogle Scholar
  171. 171.
    Shibouta, Y., Suzuki, N., Shino, A., Matsumoto, H., Terashita, Z.-I., Kondo, K., and Nishikawa, K. (1990) Pathophysiological role of ET in acute renal failure. Life Sci. 46: 1611–1618.PubMedCrossRefGoogle Scholar
  172. 172.
    Firth, J. D. and Ratcliffe, P. J. (1992) Organ distribution of the three rat ET messenger RNAs and the effects of ischemia on renal gene expression. J. Clin. Invest 90, 1023–1031.Google Scholar
  173. 173.
    Clozel, M., Löffler, B. M. and Gloor, H. (1991) Relative preservation of the responsiveness to ET-1 during reperfusion following renal ischemia in the rat. J. Cardiovasc. Pharmacol. 17(Suppl. 7 ): S313–5315.Google Scholar
  174. 174.
    Nambi, P., Pullen, M., Jugus, M., and Gellai, M. (1993) Rat kidney ET receptors in ischemia-induced acute renal failure. J. Pharmacol. Exp. Ther 264: 345–348.PubMedGoogle Scholar
  175. 175.
    Wilkes, B. M., Pearl, A. R., Mento, P. F., Maita, M. E., Macica, C. M., and Girardi, E. P. (1991) Glomerular ET receptors during initiation and maintenance of ischemic acute renal failure in rats. Am. J. Physiol 260: F110 — F118.PubMedGoogle Scholar
  176. 176.
    Vemulapalli, S., Chiu, P. J. S., Chintala, M., and Bernardino, V. (1993) Attenuation of ischemic acute renal failure by phosphoramidon in rats. Pharmacology 47: 188–193.PubMedCrossRefGoogle Scholar
  177. Kon, V., Yoshioka, T., Fogo, A., and Ichikawa, I (1989) Glomerular actions of ET in vivo. J. Clin. Invest 83:1762–1767.Google Scholar
  178. 178.
    López-Farré, A., Gómez-Garre, D., Bernabeu, F., and López-Novoa, J. (1991) A role for ET in the maintenance of post-ischaemic renal failure in the rat. J. Physiol 444: 513–522.PubMedGoogle Scholar
  179. 179.
    Mino, N., Kobayashi, M., Nakajima, A., Amano, H., Shimamoto, K., Ishikawa, K., Watanabe, K., Nishikebe, M., Yano, M., and Ikemoto, F. (1992) Protective effect of a selective ET receptor antagonist, BQ123, in ischemic acute renal failure in rats. Eur. J. Pharmacol 221: 77–83.PubMedCrossRefGoogle Scholar
  180. 180.
    Chan, L., Chittinandana, A., Shapiro, J. I., Shanley, P. F., and Schrier, R. W. (1994) Effect of an ET-receptor antagonist on ischemic acute renal failure. Am. J. Physiol 266: F135 — F138.PubMedGoogle Scholar
  181. 181.
    Gellai, M., Jugus, M., Fletcher, T. A., DeWolf, R., and Nambi, P. (1994) Reversal of postischemic acute renal failure with a selective ETA receptor antagonist in the rat. J. Clin. Invest 93: 900–906.PubMedCrossRefGoogle Scholar
  182. 182.
    Brooks, D. P., DePalma, P. D., Gellai, M., Nambi, P., Ohlstein, E. H., Elliott, J. D., Gleason, J., and Ruffolo, R. R., Jr. (1994) Non-peptide ET receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. J. Pharmacol. Exp. Ther 271: 769–775.PubMedGoogle Scholar
  183. 183.
    Gellai, M., Jugus, M., Fletcher, T., Nambi, P., Ohlstein, E. H., Elliott, J. D., and Brooks, D. P. (1995) Nonpeptide endothelin receptor antagonists. V: prevention and reversal of acute renal failure in the rat by SB 209670. J. Pharmacol. Exp. Ther 275: 200–206.PubMedGoogle Scholar
  184. 184.
    Clozel, M., Breu, V., Burri, K., Cassal, J.-M., Fischli, W., Gray, G. A., Hirth, G., Löffler, B.-M., Müller, M., Neidhart, W., and Ramuz, H. (1993) Pathophysiological role of ET revealed by the first orally active ET receptor antagonist. Nature 365: 759–761.PubMedCrossRefGoogle Scholar
  185. 185.
    Kusumoto, K., Kubo, K., Kandori, H., Kitayoshi, T., Sato, S., Wakimasu, M., Watanabe, T., and Fujino, M. (1994) Effects of a new endothelin antagonist, TAK-044, on post-ischemic acute renal failure in rats. Life Sci. 55: 301–310.PubMedCrossRefGoogle Scholar
  186. 186.
    Stingo, A. J., Clavell, A. L., Aarhus, L. L., and Burnett, J. C., Jr. (1993) Biological role for the ET-A receptor in aortic cross-clamping. Hypertension 22: 62–66.PubMedCrossRefGoogle Scholar
  187. 187.
    Brooks, D. P., DePalma, P. D., Pullen, M., and Nambi, P. (1994) Characterization of canine renal ET receptor subtypes and their function. J. Pharmacol. Exp. Ther 268: 1091–1097.PubMedGoogle Scholar
  188. 188.
    Brooks, D. P. (1996) Role of endothelin in renal function and dysfunction. Clin. Exp. Pharmacol. Physiol 23: 345–348.PubMedCrossRefGoogle Scholar
  189. 189.
    Nir, A., Clavell, A. L., Heublein, D., Aarhus, L. L., and Burnett, J. C., Jr. (1994) Acute hypoxia and endogenous renal ET. J. Am. Soc. Nephrol 4: 1920–1924.PubMedGoogle Scholar
  190. 190.
    Roubert, P., Gillard-Roubert, V., Pourmarin, L., Cornet, S., Guilmard, C., Plas, P., Pirotzky, E., Chabrier, P. E., and Braquet, P. (1993) Endothelin receptor subtypes A and B are up-regulated in an experimental model of acute renal failure. Mol. Pharmacol. 45: 182–188.Google Scholar
  191. 191.
    Karam, H., Bruneval, P., Clozel, J.-P., Loffler, B.-M., Bariety, J., and Clozel, M. (1995) Role of endothelin in acute renal failure due to rhabdomyolysis in rats. J. Pharmacol. Exp. Ther 274: 481–486.PubMedGoogle Scholar
  192. 192.
    Bunchman, T. E. and Brookshire, C. A. (1991) Cyclosporine-induced synthesis of ET by cultured human endothelial cells. J. Clin. Invest 88: 310–314.PubMedCrossRefGoogle Scholar
  193. 193.
    Nakahama, H. (1990) Stimulatory effect of cyclosporine A on ET secretion by a cultured renal epithelial cell line, LLC-PK1 cells. Eur. J. Pharmacol 180: 191, 192.Google Scholar
  194. 194.
    Moutabarrik, A., Ishibashi, M., Fukunaga, M., Kameoka, H., Takano, Y., Kokado, Y., Takahar, S., Jiang, H., Sonoda, T., and Okuyama, A. (1991) FK506 mechanism of nephrotoxicity: stimulatory effect on ET secretion by cultured kidney cells. Transplant. Proc 23: 3133–3136.PubMedGoogle Scholar
  195. 195.
    Edwards, B. S., Hunt, S. A., Fowler, M. B., Valentine, H. A., Anderson, L. M., and Lerman, A. (1991) Effect of cyclosporine on plasma ET levels in humans after cardiac transplantation. Am. J. Cardiol 67: 782–784.PubMedCrossRefGoogle Scholar
  196. 196.
    Grieff, M., Loertscher, R., Shohaib, S. A., and Stewart, D. J. (1993) Cyclosporine-induced elevation in circulating ET-1 in patients with solid-organ transplants. Transplantation 56: 880–884.PubMedCrossRefGoogle Scholar
  197. 197.
    Haug, C., Duell, T., Lenich, A., Kolb, H. J., and Grunert, A. (1995) Elevated plasma endothelin concentrations in cyclosporine-treated patients after bone marrow transplantation. Bone Marrow Transplant. 16: 191–194.PubMedGoogle Scholar
  198. 198.
    Textor, S. C., Burnett, J. C., Jr., Romero, C., Canzanello, V. J., Taler, S. J., Wiesner, R., Porayko, M., Krom, R., Gores, G., and Hay, E. (1995) Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 47: 1426–1433.PubMedCrossRefGoogle Scholar
  199. 199.
    Tanda, K., Seki, T., Kobayashi, S., Kanagawa, K., Chikaraishi, T., Togashi, M., Nonomura, K., and Koyanagi, T. (1994) In vivo effect of a selective endothelin receptor antagonist, BQ123, on renal function in cyclosporin A-treated rats. Int. J. Urol 1: 309–315.Google Scholar
  200. 200.
    Benigni, A., Perico, N., Ladny, J. R., Imberti, O., Bellizzi, L., and Remuzzi, G. (1991) Increased urinary excretion of ET-1 and its precursor, big-ET-1, in rats chronically treated with cyclosporine. Transplantation 52: 175–177.PubMedCrossRefGoogle Scholar
  201. 201.
    Abassi, Z. A., Pieruzzi, F., Nakhoul, F., and Keiser, H. R. (1996) Effects of cyclosporin A on the synthesis, excretion and metabolism of endothelin the rat. Hypertension 27: 1140–1148.PubMedCrossRefGoogle Scholar
  202. 202.
    Brooks, D. P., Ohlstein, E. H., Contino, L. C., Storer, B., Pullen, M., Caltabiano, M., and Nambi, P. (1991) Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary ET excretion and renal ET receptor number. Eur. J. Pharmacol 194: 115–117.PubMedCrossRefGoogle Scholar
  203. 203.
    Nambi, P., Pullen, M., Contino, L. C., and Brooks, D. P. (1990) Upregulation of renal ET receptors in rats with cyclosporine A-induced nephrotoxicity. Eur. J. Pharmacol 187: 113–116.PubMedCrossRefGoogle Scholar
  204. 204.
    Awazu, M., Sugiura, M., Inagami, T., Ichikawa, I., and Kon, V. (1991) Cyclosporine promotes glomerular ET binding in vivo. J. Am. Soc. Nephrol. 1: 1253–1258.Google Scholar
  205. 205.
    Takeda, M., Iwasaki, S., Hellings, S. E., Yoshida, H., Homma, T., and Kon, V. (1994) Divergent expression of ETA and ETB receptors in response to cyclosporine in mesangial cells. Am. J. Pathol 144: 473–479.PubMedGoogle Scholar
  206. 206.
    Nayler, W. G., Gu, X. H., Casley, D. J., Panagiotopoulos, S., Liu, J., and Mottram, P. L. (1989) Cyclosporine increases ET-1 binding site density in cardiac cell membranes. Biochem. Biophys. Res. Commun 163: 1270–1274.PubMedCrossRefGoogle Scholar
  207. 207.
    Iwai, J., Kanayama, Y., Negoro, N., Okamura, M., and Takeda, T. (1995) Gene expression of endothelin receptors in aortic cells from cyclosporineinduced hypertensive rats. Clin. Exp. Pharmacol. Physiol. 22: 40 /1 409.Google Scholar
  208. 208.
    Kon, V., Sugiura, M., Inagami, T., Harvie, B. R., Ichikawa, I., and Hoover, R. L. (1990) Role of ET in cyclosporine-induced glomerular dysfunction. Kidney Int. 37: 1487–1491.PubMedCrossRefGoogle Scholar
  209. 209.
    Perico, N., Dadan, J., and Remuzzi, G. (1990) Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J. Am. Soc. Nephrol 1: 76–83.PubMedGoogle Scholar
  210. 210.
    Bloom, I. T. M., Bentley, F. R., and Garrison, R. N. (1993) Acute cyclosporine-induced renal vasoconstriction is mediated by ET-1. Surgery 114: 480–488.PubMedGoogle Scholar
  211. 211.
    Brooks, D. P. and Contino, L. C. (1995) Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670. Eur. J. Pharmacol 294: 571–576.PubMedCrossRefGoogle Scholar
  212. 212.
    Fogo, A., Hellings, S. E., Inagami, T., and Kon, V. (1992) Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 42: 770–774.PubMedCrossRefGoogle Scholar
  213. 213.
    Bartholomeusz, B., Hardy, K. J., Nelson, A. S., and Phillips, P. A. (1996) Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 27: 1341–1345.PubMedCrossRefGoogle Scholar
  214. 214.
    Conger, J. D., Kim, G. E., and Robinette, J. B. (1994) Effects of ANG II, ETA and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am. J. Physiol 267: F443 - F449.Google Scholar
  215. 215.
    Davis, L. S., Haleen, S. J., Doherty, A. M., Cody, W. L., and Keiser, J. A. (1994) Effects of selective endothelin antagonists on the hemodynamic response to cyclosporin A. J. Am. Soc. Nephrol 4: 1448–1454.PubMedGoogle Scholar
  216. 216.
    Elzinga, L. W., Rosen, S., and Bennett, W. M. (1993) Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J. Am. Soc. Nephrol 42: 214–221.Google Scholar
  217. 217.
    Hunley, T. E., Fogo, A., Iwasaki, S., and Kon, V. (1995) Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J. Am. Soc. Nephrol 5: 1718–1723.PubMedGoogle Scholar
  218. 218.
    Kon, V., Hunley, T. E., and Fogo, A. (1995) Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation 60: 89–95.PubMedCrossRefGoogle Scholar
  219. 219.
    Takeda, Y., Miyamori, I., Wu, P., Yoneda, T., Furukawa, K., and Takeda, R. (1995) Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 26: 932–936.PubMedCrossRefGoogle Scholar
  220. 220.
    Binet, I., Wallnofer, A., Jones, R., and Thiel, G. (1996) Renal hemodynamic effects of an endothelin antagonist bosentan, and interaction with cyclosporin A: a placebo controlled double-blind study. J. Am. Soc. Nephrol 7: 1578.Google Scholar
  221. 221.
    Goodall, T., Kind, C. N., and Hammond, T. G. (1995) FK506-induced endothelin release by cultured rat mesangial cells. J. Cardiovasc. Pharmacol 26 (Suppl. 3): S482 — S485.PubMedGoogle Scholar
  222. 222.
    Kumano, K., Chen, J., He, M., Endo, T., and Masaki, Y. (1995) Role of endothelin in FK 506-induced renal hypoperfusion in rats. Transplant. Proc 27: 550–553.PubMedGoogle Scholar
  223. 223.
    Heyman, S. N., Clark, B. A., Kaiser, N., Spokes, K., Rosen, S., Brezis, M., and Epstein, F. H. (1992) Radiocontrast agents induce ET release in vivo and in vitro. J. Am. Soc. Nephrol. 3: 58–65.Google Scholar
  224. 224.
    Sung, J.-M., Shu, G. H. F., Tsai, J.-C., and Huang, J.-J. (1995) Radiocontrast media induced endothelin-1 mRNA expression and peptide release in porcine aortic endothelial cells. J. Formos. Med. Assoc 94: 77–86.PubMedGoogle Scholar
  225. 225.
    Margulies, K. B., Hildebrand, F. L., Heublein, D. M., and Burnett, J. C., Jr. (1991) Radiocontrast increases plasma and urinary ET. J. Am. Soc. Nephrol 2: 1041–1045.PubMedGoogle Scholar
  226. 226.
    Cantley, L. G., Spokes, K., Clark, B., McMahon, E. G., Carter, J., and Epstein, F. H. (1993) Role of ET and prostaglandins in radiocontrastinduced renal artery constriction. Kidney Int. 44: 1217–1223.PubMedCrossRefGoogle Scholar
  227. 227.
    Oldroyd, S., Slee, S.-J., Haylor, J., Morcos, S. K., and Wilson, C. (1994) Role for endothelin in the renal responses to radiocontrast media in the rat. Clin. Sci 87: 427–434.PubMedGoogle Scholar
  228. 228.
    Brooks, D. P. and DePalma, P. D. (1996) Blockade of radiocontrastinduced nephrotoxicity by the endothelin receptor antagonist, SB 209670. Nephron 72: 629–636.PubMedCrossRefGoogle Scholar
  229. 229.
    Bird, J. E., Giancarli, M. R., Megill, J. R., and Durham, S. K. (1996) Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors. J. Am. Soc. Nephrol 7: 1153–1157.PubMedGoogle Scholar
  230. 230.
    Pinzani, M., Milani, S., DeFranco, R., Grappone, C., Caligiuri, A., Gentilini, A., Tosti-Guerra, C., Maggi, M., Failli, P., Ruocco, C., and Gentilini, P. (1996) Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110: 534–548.PubMedCrossRefGoogle Scholar
  231. 231.
    Hocher, B., Zart, R., Diekmann, F., Slowinski, T., Thone-Reineke, C., Lutz, J., and Bauer, C. (1995) Role of the paracrine liver endothelin system in the pathogenesis of CC 14-induced liver injury. Eur. J. Pharmacol 293: 361–368.PubMedCrossRefGoogle Scholar
  232. 232.
    Rockey, D. C. and Weisiger, R. A. (1996) Endothelin-induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 24: 233–240.PubMedCrossRefGoogle Scholar
  233. 233.
    Moller, S., Gulberg, V., Henriksen, J. H., and Gerbes, A. L. (1995) Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J. Hepatol 23: 135–144.PubMedCrossRefGoogle Scholar
  234. 234.
    Hocher, B., Zart, R., Diekmann, F., Slowinski, T., Thone-Reineke, C., Lutz, J., and Bauer, C. (1996) Protective effects of the mixed endothelin receptor antagonist bosentan in rats with CCL4-induced liver injury. J. Cardiovasc. Pharmacol$126(Suppl. 3): S130, S131.Google Scholar
  235. 235.
    Soper, C. P. R., Latif, A. B., and Bending, M. R. (1996) Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 347: 1842–1843.PubMedCrossRefGoogle Scholar
  236. 236.
    King, A. J., Brenner, B. M., and Anderson, S. (1989) Endothelin: a potent renal and systemic vasoconstrictor peptide. Am. J. Physiol 256: F1051 — F1058.PubMedGoogle Scholar
  237. 237.
    Simonson, M. S., Wann, S., Mené, P., Dubyak, G. R., Kester, M., Nakazato, Y., Sedor, J. R., and Dunn, M. J. (1989) Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J. Clin. Invest 83: 708–712.PubMedCrossRefGoogle Scholar
  238. 238.
    Bakris, G. L. and Re, R. N. (1993) Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am. J. Physiol 264: F937 — F942.PubMedGoogle Scholar
  239. 239.
    Ishimura, E., Shouji, S., Nishizawa, Y., Morii, H., and Kashgarian, M. (1991) Regulation of mRNA expression for extracellular matrix (ECM) by cultured rat mesangial cells (MCs). J. Am. Soc. Nephrol 2: 546 (abst.).Google Scholar
  240. 240.
    Gomez-Gaffe, D., Ruiz-Ortega, M., Ortego, M., Largo, R., Lopez-Armada, M. J., Plaza, J. J., Gonzalez, E., and Egido, J. (1996) Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 27: 885–892.CrossRefGoogle Scholar
  241. 241.
    Zoja, C., Orisio, S., Perico, N., Benigni, A., Morigi, M., Benatti, L., Rambaldi, A., and Remuzzi, G. (1991) Constitutive expression of ET gene in cultured human mesangial cells and its modulation by transforming growth factor43, thrombin, and a thromboxane A2 analog. Lab. Invest 64: 16–20.PubMedGoogle Scholar
  242. 242.
    Horie, M., Uchida, C., Yanagisawa, M., Matsushita, Y., Kurokawa, K., and Ogata, E. (1991) Mechanisms of ET-1 mRNA and peptides induction by TGF 3 and TPA in MDCK cells. J. Cardiovasc. Pharmacol 17 (Suppl. 7): S222 — S225.PubMedCrossRefGoogle Scholar
  243. 243.
    Schulz, E., Ruschitzka, F., Lueders, S., Heydenbluth, R., Schrader, J., and Muller, G. A. (1995) Effects of endothelin on hemodynamics, Prostaglandins, blood coagulation and renal function. Kidney Int. 47: 795–801.PubMedCrossRefGoogle Scholar
  244. 244.
    Brooks, D. P., Contino, L. C., Storer, B., and Ohlstein, E. H. (1991) Increased ET excretion in rats with renal failure induced by partial nephrectomy. Br. J. Pharmacol 104: 987–989.PubMedCrossRefGoogle Scholar
  245. 245.
    Benigni, A., Perico, N., Gaspari, F., Zoja, C., Bellizzi, L., Gabanelli, M., and Remuzzi, G. (1991) Increased renal ET production in rats with reduced renal mass. Am. J. Physiol 260: F331 — F339.PubMedGoogle Scholar
  246. 246.
    Morabito, E., Corsico, N., and Arrigoni-Martelli, E. (1994) Endothelins urinary excretion is increased in spontaneously diabetic rats: BB/BB. Life Sci. 25: PL 13–18.Google Scholar
  247. 247.
    Orisio, S., Benigni, A., Bruzzi, I., Corna, D., Perico, N., Zoja, C., Benatti, L., and Remuzzi, G. (1993) Renal ET gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 43: 354–358.Google Scholar
  248. 248.
    Fukui, M., Nakamura, T., Ebihara, I., Osada, S., Tomino, Y., Masaki, T., Goto, K., Furuichi, Y., and Koide, H. (1993) Gene expression for ETs and their receptors in glomeruli of diabetic rats. J. Lab. Clin. Med 122: 149–156.Google Scholar
  249. 249.
    Nakamura, T., Ebihara, I., Fukui, M., Osada, S., Tamino, Y., Masaki, T., Goto, K., Furuichi, Y., and Koide, H. (1995) Modulation of glomerular endothelin and endothelin receptor gene expression in aminonucleosideinduced nephrosis. J. Am. Soc. Nephrol 5: 1585–1590.PubMedGoogle Scholar
  250. 250.
    Nakamura, T., Ebihara, I., Fukui, M., Osada, S., Tomino, Y., Masaki, T., Goto, K., Furuichi, Y., and Koide, H. (1993) Increased ET and ET receptor mRNA expression in polycystic kidneys of cpk mice. J. Am. Soc. Nephrol 4: 1064–1072.PubMedGoogle Scholar
  251. 251.
    Hocher, B., Liefeldt, L., Thone-Reineke, C., Orzechowski, H.-D., Distler, A., Bauer, C., and Paul, M. (1996) Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 28: 196–201.PubMedCrossRefGoogle Scholar
  252. 252.
    Benigni, A., Zoja, C., Corna, D., Orisio, S., Longaretti, L., Bertani, T., and Remuzzi, G. (1993) A specific ET subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 44: 440–444.PubMedCrossRefGoogle Scholar
  253. 253.
    Nakamura, T., Ebihara, I., Tomino, Y., and Koide, H. (1995) Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. 47: 481–489.PubMedCrossRefGoogle Scholar
  254. 254.
    Benigni, A., Zoja, C., Corna, D., Orisio, S., Facchinetti, D., Benatti, L., and Remuzzi, G. (1996) Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am. J. Kid. Dis 27: 416–423.PubMedCrossRefGoogle Scholar
  255. 255.
    Nabokov, A., Amann, K., Wagner, J., Gehlen, F., Munter, K., and Ritz, E. (1996) Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol. Dial. Transplant 11: 514–520.PubMedCrossRefGoogle Scholar
  256. 256.
    Pollock, D. M. and Polakowski, J. S. (1997) ETA receptor blockade prevents hypertension associated with exogenous ET-1 but not renal mass reduction in the rat. J. Am. Soc. Nephrol 8: 1054–1060.PubMedGoogle Scholar
  257. 257.
    Ohta, K., Hirata, Y., Shichiri, M., Ichioka, M., Kubota, T., and Marumo, F. (1991) Cisplatin-induced urinary ET excretion. JAMA 265: 1391, 1392.Google Scholar
  258. 258.
    Heyman, S. N., Clark, B. A., Kaiser, N., Epstein, F. H., Spokes, K., Rosen, S., and Brezis, M. (1992) In vivo and in vitro studies on the effect of amphotericin B on ET release. J. Antimicrob. Chemother 29: 69–77.CrossRefGoogle Scholar
  259. 259.
    Morise, Z., Ueda, M., Aiura, K., Endo, M., and Kitajima, M. (1994) Pathophysiologic role of endothelin-1 in renal function in rats with endotoxin shock. Surgery 115: 199–204.PubMedGoogle Scholar
  260. 260.
    Kelleher, J. P., Shah, V., Godley, M. L., Wakefield, A. J., Gordon, I., Ransley, P. G., Snell, M. E., and Risdon, R. A. (1992) Urinary endothelin (ET1) in complete ureteric obstruction in the miniature pig. Urol. Res 20: 63–65.PubMedCrossRefGoogle Scholar
  261. 261.
    Langenstroer, P., Tang, R., Shapiro, E., Divish, B., Opgenorth, T., and Lepor, H. (1993) Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J. Urol 149: 495–499.Google Scholar
  262. 262.
    Rossi, G. P., Albertin, G., Franchin, E., Sacchetto, A., Cesari, M., Palu, G., and Pessina, A. C. (1995) Expression of the endothelin-converting enzyme gene in human tissues. Biochem. Biophys. Res. Commun 211: 249–253.PubMedCrossRefGoogle Scholar
  263. 263.
    Kondo, S., Morita, T., and Tashima, Y. (1995) Benign prostatic hypertrophy affects the endothelin receptor density in the human urinary bladder and prostate. Urol. Int 54: 198–203.PubMedCrossRefGoogle Scholar
  264. 264.
    Kobayashi, S., Tang, R., Wang, B., Opgenorth, T., Langenstoer, P., Shapiro, E., and Lepor, H. (1994) Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol. Pharmacol 45: 306–311.PubMedGoogle Scholar
  265. 265.
    Le Brun, G., Moldovan, F., Aubin, P., Ropiquet, F., Cussenot, O., and Fiet, J. (1996) Identification of endothelin receptors in normal and hyperplasic human prostate tissues. Prostate 28: 379–384.PubMedCrossRefGoogle Scholar
  266. 266.
    Kondo, S., Morita, T., and Tashima, Y. (1994) Endothelin receptor density in human hypertrophic and non-hypertrophic prostate tissue. J. Exp. Med 172: 381–384.Google Scholar
  267. 267.
    Moriyama, N., Kurimoto, S., Miyata, N., Yamaura, H., Yamazaki, R., Sudoh, K., Inagaki, O., Takenaka, T., and Kawabe, K. (1996) Decreased contractile effect of endothelin-1 on hyperplastic prostate. Gen. Pharmacol 6: 1061–1065.Google Scholar
  268. 268.
    Kusuhara, M., Yamaguchi, K., Nagasaki, K., Hayashi, C., Suzaki, A., Hori, S., Handa, S., Nakamura, Y., and Abe, K. (1990) Production of endothelin in human cancer cell lines. Cancer Res. 50: 3257–3261.PubMedGoogle Scholar
  269. 269.
    Giaid, A., Hamid, Q. A., Springall, D. R., Yanagisawa, M., Shinmi, O., Sawamura, T., Masaki, T., Kimura, S., Corrin, B., and Polak, J. M. (1990) Detection of endothelin immunoreactivity and mRNA in pulmonary tumors. J. Pathol 162: 15–22.PubMedCrossRefGoogle Scholar
  270. 270.
    Shichiri, M., Hirata, Y., Nakajima, T., Ando, K., Imai, T., Yanagisawa, M., Masaki, T., and Marumo, F. (1991) Endothelin-1 is an autocrine/ paracrine growth factor for human cancer cell lines. J. Clin. Invest 87: 1867–1871.PubMedCrossRefGoogle Scholar
  271. 271.
    Oikawa, T., Kushuhara, M., Ishikawa, S., Hitomi, J., Kono, A., Iwanaga, T., and Yamaguchi, K. (1994) Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells. Br. J. Cancer 69: 1059–1064.PubMedCrossRefGoogle Scholar
  272. 272.
    Patel, K. V. and Schrey, M. P. (1995) Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: a proposed mitogen for human breast fibroblasts. Br. J. Cancer 71: 442–447.PubMedCrossRefGoogle Scholar
  273. 273.
    Nakamuta, M., Ohashi, M., Tabata, S., Tanabe, Y., Goto, K., Naruse, M., Naruse, K., Hiroshe, K., and Nawata, H. (1993) High plasma concentration of endothelin-like immunoreactivities in patients with hepatocellular carcinoma. Am. J. Gastroenterol 88: 248–252.PubMedGoogle Scholar
  274. 274.
    Economos, K., MacDonald, P. C., and Casey, M. L. (1992) Endothelin-1 gene expression and biosynthesis in human endometrial HEC-1A cancer cells. Cancer Res. 52: 554–557.PubMedGoogle Scholar
  275. 275.
    Inagaki, H., Bishop, A. E., Eimoto, T., and Polak, J. M. (1992) Autoradiographic localization of endothelin-1 binding sites in human colonic cancer tissue. J. Pathol 168: 263–267.PubMedCrossRefGoogle Scholar
  276. 276.
    Nelson, J. B., Chan-Tack, K., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., and Simons, J. W. (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56: 663–668.PubMedGoogle Scholar
  277. 277.
    Takuwa, Y., Masaki, T., and Yamashita, K. (1990) The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem. Biophys. Res. Commun 170: 998–1005.PubMedCrossRefGoogle Scholar
  278. 278.
    Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., and Simons, J. W. (1995) Identification of endothelin1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature 1:944–949.Google Scholar
  279. 279.
    Oliver, F. J., de la Rubia, G., Feener, E. P., Lee, M. E., Loeken, M. R., Shiba, T., Quertermous, T., and King, G. L. (1991) Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J. Biol. Chem 266: 23251–23256.PubMedGoogle Scholar
  280. 280.
    Takahashi, K., Ghatei, M. A., Lam, H.-C., O’Halloran, D. J., and Bloom, S. R. (1990) Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33: 306–310.PubMedCrossRefGoogle Scholar
  281. 281.
    Totsune, K., Sone, M., Takahashi, K., Ohneda, M., Itoi, K., Murakami, O., Saito, T., Mouri, T., and Yoshinaga, K. (1991) Immunoreactive endothelin in urine of patients with and without diabetes mellitus. J. Cardiovasc. Pharmacol. 17(Suppl. 7 ): 5423–5424.Google Scholar
  282. 282.
    Nugent, A. G., McGurk, C., Hayes, J. R., and Johnston, G. D. (1996) Impaired vasoconstriction to endothelin-1 in patients with NIDDM. Diabetes 45: 105–107.PubMedCrossRefGoogle Scholar
  283. 283.
    Kawamura, M., Ohgawara, H., Naruse, M., Suzuki, N., Iwasaki, N., Naruse, K., Hori, S., Demura, H., and Omori, Y. (1992) Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 15: 1396, 1397.Google Scholar
  284. 284.
    Kaiser, H. J., Flammer, J., Wenk, M., and Luscher, T. (1995) Endothelin1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefes. Arch. Clin. Exp. Ophthalmol 233: 484–488.PubMedCrossRefGoogle Scholar
  285. 285.
    Kawaguchi, Y., Suzuki, K., Hara, M., Hidaka, T., Ishizuka, T., Kawagoe, M., and Nakamura, H. (1994) Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann. Rheum. Dis 53: 506–510.PubMedCrossRefGoogle Scholar
  286. 286.
    Watschinger, B., Vychytil, A., Schuller, M., Hartter, E., and Traindl, O. (1991) The pathophysiologic role of ET in acute vascular rejection after renal transplantation. Transplantation 52: 743–746.PubMedCrossRefGoogle Scholar
  287. 287.
    Wallace, J. L., Cirino, G., De Nucci, G., McKnight, W., and MacNaughton, W. K. (1989) Endothelin has potent ulcerogenic and vasoconstrictor actions in the stomach. Am. J. Physiol 256: G661 — G666.Google Scholar
  288. 288.
    Murch, S. H., Braegger, C. P., Sessa, W. C., and MacDonald, T. T. (1992) High endothelin-1 immunoreactivity in Crohn’s disease and ulcerative colitis. Lancet 339: 381–385.Google Scholar
  289. 289.
    Rachmilewitz, D., Eliakim, R., Ackerman, Z., and Karmeli, F. (1992) Colonic endothelin-1 immunoreactivity in active ulcerative colitis. Lancet 339: 1062.PubMedCrossRefGoogle Scholar
  290. 290.
    Hosoda, K., Hammer, R. E., Richardson, J. A., Greenstein Baynash, A., Cheung, J. C., Giaid, A., and Yanagisawa, M. (1994) Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267–1276.PubMedCrossRefGoogle Scholar
  291. 291.
    Baynash, A. G., Hosoda, K., Giaid, A., Richardson, J. A., Emotom, N., Hammer, R. E., and Yanagisawa, M. (1994) Interaction of endothelin-3 with endothelin B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79: 1277–1285.PubMedCrossRefGoogle Scholar
  292. 292.
    Hofstra, R. M., Osinga, J., Tan Sindhunata, G., Wu, Y., Kamsteeg, E. J., Stulp, R. P., van Ravenswaaij, A. C., Majoor Krakauer, D., Angrist, M., Chakravarti, A., Meijers, C., and Buys, C. H. (1996) A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nat. Genet 12: 445–447.PubMedCrossRefGoogle Scholar
  293. 293.
    Edery, P., Attie, T., Amiel, J., Pelet, A., Eng, C., Hofstra, R. M., Martelli, H., Bidaud, C., Munnich, A., and Lyonnet, S. (1996) Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (ShahWaardenburg syndrome). Nat. Genet 12: 442–444.PubMedCrossRefGoogle Scholar
  294. 294.
    Tsuboi, R., Sato, C., Shi, C.-M., Nakamura, T., Sakurai, T., and Ogawa, H. (1994) Endothelin-1 acts as an autocrine growth factor for normal human keratinocytes. J. Cell Physiol 159: 213–220.PubMedCrossRefGoogle Scholar
  295. 295.
    Bagnato, A., Venuti, A., DiCastro, V., and Marcante, M. L. (1995) Identification of the ETA receptor subtype that mediates endothelin induced autocrine proliferation of normal human keratinocytes. Biochem. Biophys. Res. Commun 209: 80–86.PubMedCrossRefGoogle Scholar
  296. 296.
    Zachariae, H., Heickendorff, L., and Bjerring, P. (1996) Plasma endothelin in psoriasis—possible relations to therapy and toxicity. Acta. Dermatol. Venereol 76: 442, 443.Google Scholar
  297. 297.
    Teraki, E., Tajima, S., Manaka, I., Kawashima, M., Miyagishi, M., and Imokawa, G. (1996) Role of endothelin-1 in hyperpigmentation in seborrheic keratosis. Br. J. Dermatol 96: 918–923.CrossRefGoogle Scholar
  298. 298.
    Kurihara, Y., Kurihara, H., Suzuki, H., Kodama, T., Maemura, K., Nagai, R., Oda, H., Kuwaki, T., Cao, W.-H., Kamada, N., Jishage, K., Ouchi, Y., Azuma, S., Toyoda, Y., Ishikawa, T., Kumada, M., and Yazaki, Y. (1994) Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368: 703–710.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • David P. Brooks
  • Diane K. Jorkasky
  • Martin I. Freed
  • Eliot H. Ohlstein

There are no affiliations available

Personalised recommendations